Kiniksa Pharmaceuticals International, plc (KNSA) Operating Margin
- Operating margin · 12 months: Value 12.36%; Formula and calculation Operating income / revenue. Period ending 2026-03-31..
Operating margin
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 12.36% | Operating income / revenue. Period ending 2026-03-31. $93.22M ÷ $754.04M × 100 ≈ 12.36% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 93.22M USD | Operating Income (Loss) |
| Revenue | 754.04M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 80.60M USD | Cost of Goods and Services Sold |
| Research and development | 105.00M USD | Research and Development Expense |
| Selling, general and administration | 213.89M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $93.22M | $754.04M | $80.60M | $105.00M | $213.89M | 12.36% |
| 2025-12-31 | $77.22M | $677.56M | $77.67M | $96.85M | $196.27M | 11.40% |
| 2025-09-30 | $38.15M | $597.97M | $74.62M | $97.46M | $180.03M | 6.38% |
| 2025-06-30 | $4.47M | $529.33M | $74.48M | $99.35M | $177.33M | 0.85% |
| 2025-03-31 | $-15.80M | $481.17M | $68.19M | $104.61M | $172.86M | -3.28% |
| 2024-12-31 | $-45.62M | $423.24M | $60.91M | $111.62M | $168.01M | -10.78% |
| 2024-09-30 | $-26.24M | $384.10M | (m) | $96.46M | $164.22M | -6.83% |
| 2024-06-30 | $-27.50M | $338.93M | (m) | $87.51M | $152.28M | -8.12% |
| 2024-03-31 | $-30.54M | $301.77M | (m) | $87.26M | $139.06M | -10.12% |
| 2023-12-31 | $-25.20M | $270.26M | (m) | $76.10M | $129.43M | -9.32% |
| 2023-09-30 | $-19.23M | $248.75M | (m) | $70.44M | $119.90M | -7.73% |
| 2023-06-30 | $38.11M | $280.84M | (m) | $69.81M | $110.11M | 13.57% |
| 2023-03-31 | $21.90M | $236.34M | (m) | $59.84M | $104.78M | 9.26% |
| 2022-12-31 | $9.77M | $220.18M | (m) | $65.49M | $97.95M | 4.44% |
| 2022-09-30 | $-32.41M | $177.04M | (m) | $78.53M | $93.48M | -18.30% |
| 2022-06-30 | $-109.48M | $90.00M | (m) | $81.28M | $89.56M | -121.65% |
| 2022-03-31 | $-130.67M | $70.73M | (m) | $91.43M | $87.57M | -184.74% |
| 2021-12-31 | $-156.64M | $38.54M | $9.10M | $99.30M | $85.95M | -406.38% |
| 2021-09-30 | $-173.40M | (m) | (m) | $109.26M | (m) | (m) |
| 2021-06-30 | $-185.95M | (m) | (m) | $121.44M | (m) | (m) |
| 2021-03-31 | $-177.26M | (m) | (m) | $119.82M | (m) | (m) |
| 2020-12-31 | $-157.36M | (m) | (m) | $112.04M | (m) | (m) |
| 2020-09-30 | $-137.05M | (m) | (m) | $97.53M | (m) | (m) |
| 2020-06-30 | $-124.27M | (m) | (m) | $88.13M | (m) | (m) |
| 2020-03-31 | $-131.70M | (m) | (m) | $96.65M | (m) | (m) |
| 2019-12-31 | $-169.96M | (m) | (m) | $135.00M | (m) | (m) |
| 2019-09-30 | $-181.52M | (m) | (m) | $148.24M | (m) | (m) |
| 2019-06-30 | $-177.23M | (m) | (m) | $146.87M | (m) | (m) |
| 2019-03-31 | $-159.47M | (m) | (m) | $133.22M | (m) | (m) |
| 2018-12-31 | $-108.16M | (m) | (m) | $86.60M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-65.40M | (m) | (m) | $56.36M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.